This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HUMAW

Humacyte (HUMAW) Stock Price, News & Analysis

Humacyte logo

About Humacyte Stock (NASDAQ:HUMAW)

Key Stats

Today's Range
$0.0009
▼
$0.0009
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.40
Volume
N/A
Average Volume
22,203 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Humacyte, Inc. is a biotechnology company developing implantable, bioengineered human tissues for use in vascular repair and other medical applications. Its primary technology is the human acellular vessel (HAV), a tissue-engineered vascular graft designed to provide a durable alternative to synthetic grafts and donated blood vessels.

Humacyte’s HAV platform is being studied for potential use in vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, and coronary artery bypass procedures. The company’s products are investigational unless specifically approved by regulators for a particular use, and its development programs are subject to clinical and regulatory review.

Humacyte was founded by biomedical engineer and physician Laura Niklason, who serves as the company’s chief executive officer and has led the development of its regenerative-medicine platform. The company is based in Durham, North Carolina, and its clinical development activities are conducted through research and medical collaborations in the United States and other regions.

AI Generated. May Contain Errors.

Receive HUMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HUMAW Stock News Headlines

Humacyte Earnings Call Signals Stronger Commercial Momentum
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
Transcript : Humacyte, Inc., Q3 2026 Earnings Call, Nov 10, 2026
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HUMAW
CIK
1818382
Fax
N/A
Employees
150
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$2.12 million
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:HUMAW) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners